These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19641474)

  • 1. Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy.
    Dooms C; Verbeken E; Stroobants S; Vansteenkiste J
    J Thorac Oncol; 2009 Oct; 4(10):1221-5. PubMed ID: 19641474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
    Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
    J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
    Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
    J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer.
    Masarykova A; Scepanovic D; Povinec P; Bires P; Lederleitner D; Pobijakova M
    Bratisl Lek Listy; 2018; 119(3):133-138. PubMed ID: 29536740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers.
    Nakamura H; Hirata T; Kitamura H; Nishikawa J
    Ann Thorac Cardiovasc Surg; 2009 Oct; 15(5):304-10. PubMed ID: 19901884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.
    Hoekstra CJ; Stroobants SG; Hoekstra OS; Vansteenkiste J; Biesma B; Schramel FJ; van Zandwijk N; van Tinteren H; Smit EF
    Lung Cancer; 2003 Feb; 39(2):151-7. PubMed ID: 12581567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
    Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.
    van Baardwijk A; Dooms C; van Suylen RJ; Verbeken E; Hochstenbag M; Dehing-Oberije C; Rupa D; Pastorekova S; Stroobants S; Buell U; Lambin P; Vansteenkiste J; De Ruysscher D
    Eur J Cancer; 2007 Jun; 43(9):1392-8. PubMed ID: 17512190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
    Kim SJ; Hwang SH; Kim IJ; Lee MK; Lee CH; Lee SY; Lee EY
    J Exp Clin Cancer Res; 2010 Jun; 29(1):69. PubMed ID: 20540786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer.
    Furukawa T; Miyata Y; Kushitani K; Mimae T; Tsutani Y; Takeshima Y; Okada M
    Jpn J Clin Oncol; 2015 Dec; 45(12):1154-61. PubMed ID: 26386467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.
    Schuurbiers OC; Meijer TW; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; van der Drift MA; van der Heijden EH; Oyen WJ; Visser EP; Span PN; Bussink J
    J Thorac Oncol; 2014 Oct; 9(10):1485-93. PubMed ID: 25170642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of 18F-FDG PET parameters in patients with locally advanced non-small cell lung cancer treated with induction chemotherapy.
    Lee HY; Choi WH; Yoo IR; Park JK; Sung SW; Kim YS; Kang JH
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):70-74. PubMed ID: 31782256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
    J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.
    Even AJG; Reymen B; La Fontaine MD; Das M; Jochems A; Mottaghy FM; Belderbos JSA; De Ruysscher D; Lambin P; van Elmpt W
    Acta Oncol; 2017 Nov; 56(11):1591-1596. PubMed ID: 28840770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.
    Kaira K; Endo M; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Tsuya A; Nakamura Y; Naito T; Hayashi I; Kondo H; Nakajima T; Yamamoto N
    Lung Cancer; 2011 Feb; 71(2):144-50. PubMed ID: 20646779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
    Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
    Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.